Rokit Healthcare, Inc.
KKRX:37690016,910.00
KRW
-1,110.00
(-6.16%)
ISIN
KR7376900007
Return %
Stock
S&P 500
1Y
-54.85
14.39
3Y
- -
81.42
5Y
- -
68.62
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- CEO
- Seok-Hwan Yoo
- Full Time Employees
- 90
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Seoul South Korea
- IPO Date
- May 12, 2025
- Website
- rokit.co.kr
- Similar Companies
- Business
- ROKIT Healthcare, Inc. is a South Korea-based biotechnology and medical device company that develops artificial intelligence-driven, patient-specific organ and tissue regeneration platforms. Founded in 2012 and headquartered in Seoul, South Korea, the company specializes in autologous regenerative medicine, biomedical engineering, and longevity solutions. ROKIT Healthcare provides point-of-care therapeutics designed to treat intractable chronic diseases by utilizing patient-derived cells to regenerate damaged tissues and minimize immune rejection across healthcare markets in Asia-Pacific, North America, Europe, and the Middle East. The company offers a diversified commercial and clinical portfolio structured into regenerative platforms, biomedical equipment, biomaterials, and diagnostic solutions comprising: Dr. INVIVO series medical 3D and 4D bioprinters, including multi-head bioprinting systems engineered for sterile point-of-care clinical use in surgical theaters; autologous tissue regeneration systems and single-use disposable surgical kits for dermal regeneration in diabetic foot ulcers (DFU), cartilage repair in osteoarthritis, and renal tissue regeneration in chronic kidney disease (CKD); proprietary biomaterials and cellular substrates, including HumaTein human-derived whole extracellular matrix and Huma Media specialized cell culture formulations; EpiTem and EpiTem-2 reconstructed 3D human epidermis models utilized for non-clinical pharmaceutical and cosmetic toxicity, safety verification, and alternative-to-animal efficacy testing; longevity and cellular wellness formulations, including nicotinamide mononucleotide (NMN) dietary supplements distributed through its subsidiary ROKIT America, Inc.; and single-cell RNA sequencing, genomic analysis, and AI-enabled early diagnostic platforms for disease profiling. In recent developments, ROKIT Healthcare completed its public listing on the KOSDAQ market (KRX:376900) to accelerate global commercial expansion and clinical trial pipelines. The company has broadened its international presence through strategic alliances, including an agreement with the Master Investment Group in the United Arab Emirates to establish a regional joint venture, ROKIT MENA, serving the Middle East, North Africa, and European territories. In the United States, ROKIT Healthcare formed a strategic collaboration with Northwell Health focused on wound care and skin cancer interventions, conducted joint validation research with Harvard Medical School, established a commercial partnership with a U.S.-based diagnostics firm for AI-guided early screening technologies, and initiated preparations for a prospective Nasdaq listing of its subsidiary ROKIT America. Furthermore, the company expanded its commercial footprint in China through entry into the Boao Lecheng International Medical Tourism Pilot Zone in Hainan and secured regulatory clearance to commence first-in-human clinical trials for autologous kidney regeneration surgery.